American Association for Cancer Research (AACR) 2021 Resources
Fast, No-Wash Lumit™ Immunoassays
Quantify proteins or small molecules without tedious wash steps! Our homogenous Lumit™ Immunoassays are sensitive, have broad dynamic range and can be completed in 70 minutes or less. They provide a simple and fast alternative to conventional immunoassays.
Learn how Lumit™ technology can help you get results faster in this free webinar.
What are you interested in? Explore new products in these fields:
Bioluminescent assays can help determine the ability of compounds to bind or inhibit kinases in biochemical and cellular formats, and are amenable to high-throughput or selectivity profiling. Our new NanoBRET™ Target Engagement Assays enable you to quantify live-cell target engagement at all described drug binding sites within the RAS-RAF-MEK-ERK pathway, including RAS switch I/II and II pockets. Email us to learn more about these assays.
View this 26-minute presentation describing the use of NanoBRET to quantify live-cell target engagement at RAS and downstream effectors.
It’s now possible to measure two orthogonal markers of immunogenic cell death:
1. HMGB1 release with the homogeneous no-wash Lumit™ HMGB1 Immunoassay. Email us to learn more about this assay.
2. Kinetic release of extracellular ATP with our new RealTime-Glo™ Extracellular ATP Assay. View video to see how easy it can be to measure extracellular ATP in real-time.
Get more physiologically relevant data out of your 3D culture samples with optimized assays for viability, cytotoxicity, apoptosis, and energy metabolism. The new Caspase-Glo® 3/7 3D Assay measures caspase-3 and-7 activities in apoptotic 3D cultures using a simple add-mix-measure protocol.
Our functional bioassays can interrogate immune checkpoint modulation, T cell retargeting, cytokine and growth factor signaling, tumor antigen-specific cell killing, and Fc effector activity.
The new PBMC ADCC Assay provides a simple, add-mix-read format with ADCC-qualified human PBMCs, a choice of target cells expressing HiBiT fusion protein and corresponding PBMC ADCC Bioassay Kit. Learn how the assay works in this video.
The quantity and sequences of ccfDNA molecules found in plasma can indicate the presence of a tumor and offer valuable insights into its characteristics. You can automate ccfDNA extraction from plasma with the new Maxwell® RSC ccfDNA Plasma Kit or high-throughput Maxwell® HT ccfDNA Kit.
Register for the 3-Part ccfDNA Webinar Series to learn more about the use of ccfDNA in oncology research and techniques to maximize results.
Our easy-to-use nucleic acid purification reagents cover a full range of sample throughput needs—from manual solutions through benchtop automation to plate-based systems for high-throughput processing. Learn about automated DNA and RNA extraction from FFPE tumor samples, and miRNA purification from tissue, plasma or serum.
With many urgent challenges and uncertain outcomes, molecular oncology research requires comprehensive support and resources. We believe in science-driven solutions and personalized service for scientists working with any type of cancer research. Explore our collection of molecular oncology resources, or chat with a scientist to work through your specific needs.
MSI status is an important biomarker for immunotherapeutic response in cancer patients, making it an increasingly relevant tool in genetic- and immune-oncology. We currently offer microsatellite instability testing products for research use globally, and for IVD use in certain countries throughout Europe.
The latest addition to our portfolio is the new LMR MSI Analysis System, a PCR-based method for re-evaluating challenging tumor samples to determine true microsatellite instability status. The longer base-pair shifts exhibited by the LMR system allow you to make a more confident assessment of MSI status, especially in extracolonic cancer tumors which tend to have fewer and smaller shifts in loci.
What is Microsatellite Instability (MSI)?
New CE System for Fragment Analysis and Sanger Sequencing
The Spectrum Compact CE System is a Sanger sequencing instrument used in oncology research applications for molecular profiling of cancers. It can be used to detect and verify the presence of mutant alleles in tumor tissue.
High-Performance Microplate Reader
GloMax® plate readers have high sensitivity and wide dynamic range, so you can accurately detect high and low signals on the same plate. Easily detect luminescence, fluorescence, absorbance, BRET and FRET with the touch of a button!
Reproducible, MoA-Reflecting Reporter-Based Bioassays to Enable Drug Development of Biosimilars and Biobetters
Presented by: Brad Swanson
A Homogenous PBMC ADCC Bioassay Enables Bridging Studies with ADCC Reporter Bioassays in Immunotherapy Monoclonal Antibody Development
Presented by: Gopal Krishnan
Improved DAMP Assays for the In Vitro Assessment of Immunogenic Cell Death
Presented by: Andrew Niles
An Integrated Workflow for Microsatellite Instability with a Novel MSI Panel
Presented by: Samantha Lewis
Novel Bioluminescent Bioassays for the Discovery and Development of Molecular and Cellular T Cell-Redirecting Cancer Therapy
Presented by: Vanessa Ott
Cell-Based Reporter Bioassays for the Development of Fc-Functional and Fc-Silent SIRPa/CD47 Checkpoint Inhibitors
Presented by: Jamison Grailer
MoA-Based Potency Bioassays for Immunotherapy Programs Targeting Immune Checkpoint Receptors
Presented by: Zhi-Jie (Jey) Cheng